News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

 

Management of glioblastoma.


Posted on: 11/28/2007

Expert Opin Pharmacother. 2007 Dec;8(18):3133-3146.


Management of glioblastoma.

Aoki T, Hashimoto N, Matsutani M.

1Kitano Hospital, Department of Neurosurgery, Brain Tumour Center, 2-4-20 Ohgimachi, Kita-ku, Osaka, Japan +81 6 6312 1221 ; +81 6 6361 0588 ; tomokazu@kitano-hp.or.jp , 2Kyoto University, Department of Neurosurgery, 54 Kawaracho, Shougoinn, Sakyo-ku, Kyoto, Japan, 3Saitama Medical University, Department of Neurosurgery and Neuro-Oncology, International Medical Center, 1397-1 Yamane Hidaka-shi, Saitama, Japan.

Glioblastoma multiforme (GBM) are among the most devastating neoplasms claiming the lives of patients within a median of 1 year after diagnosis. Treatment of GBM requires a multidisciplinary approach. Treatments include surgery, radiotherapy, chemotherapy and so on. Temozolomide (TMZ) has emerged as an active agent against malignant gliomas. On the basis of the work by the European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada, concurrent radiotherapy and the oral alkylating agent TMZ followed by adjuvant TMZ has become the standard of care for patients with newly diagnosed GBM, although the methylation status of the O(6)-mehylguanine-DNA methyltransferase promoter is predictive for survival of GBM patients. Gliadel is a biodegradable polymer wafer impregnated with carmustine. Gliadel has been one of the few treatment modalities to demonstrate a statistical benefit in patients with malignant glioma. These new FDA approved drugs advanced the treatment of malignant glioma, but more progress is needed. Patients require improvements in chemotherapy, surgery, radiotherapy, molecular targeted therapy, immunotoxin using the convection-enhanced delivery and more.

PMID: 18035958 [PubMed - as supplied by publisher]

Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740